Thyrocare Technologies · NSE: THYROCARE · BSE: 539871
Q4 FY21 results · Jan–Mar 2021
Thyrocare Technologies reported revenue from operations of ₹146.84 crore (up 44.8% from Q4 FY20) and net profit of ₹37.75 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 146.84 | 101.44 | +44.8% | 138.27 | +6.2% |
| Other income | 3.64 | 2.06 | +76.7% | 2.58 | +41.1% |
| Total income | 150.48 | 103.50 | +45.4% | 140.85 | +6.8% |
| Profit before share of associates & JVs and tax | 47.45 | 17.59 | +169.8% | 44.06 | +7.7% |
| Share of profit/(loss) of associates & JVs | 0.18 | (0.02) | 0.06 | ||
| Net profit for the period | 37.75 | (1.59) | Turned profit | 32.39 | +16.5% |
| EPS, basic (₹) | 7.14 | (0.30) | Turned profit | 6.13 | +16.5% |
| Net margin (%) | 25.7 | -1.6 | 23.4 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 139.16 | 93.62 | +48.6% | 132.17 | +5.3% |
| Other income | 2.48 | 2.47 | +0.4% | 2.96 | −16.2% |
| Total income | 141.64 | 96.09 | +47.4% | 135.13 | +4.8% |
| Profit before tax | 47.41 | (18.27) | Turned profit | 45.97 | +3.1% |
| Net profit for the period | 35.34 | (18.09) | Turned profit | 34.24 | +3.2% |
| EPS, basic (₹) | 6.69 | (3.43) | Turned profit | 6.48 | +3.2% |
| Net margin (%) | 25.4 | -19.3 | 25.9 |
Consolidated
- Filed with BSE
- 10 May 2021, 20:32 IST
- Board meeting
- 08 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 May 2021, 20:32 IST
- Board meeting
- 08 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE